Skip to content
★ Sign in to follow
Freenome, Inc. logo

Freenome, Inc. Stock: price and insider trades · United States

US·Mcap US$1.4BHealth Care

Insider Decl.
18
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a

Freenome, Inc.: what insiders have been doing

Freenome, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). In the past year (17 November 2025 to 17 November 2026), 15 filings came from 9 insiders.

Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

Compared with its exchange (3,169 companies, median 24 filings), a count of 15 filings is below the norm. For the fiscal year to 31 December 2025, the annual 10-K puts net income at 837,468 USD.

Over the last twelve months, not one insider purchase of Freenome, Inc. stock was filed. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Analyst consensus: bullish or bearish?

Analysts rate Freenome, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$18.00.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 22,410 of 29,078 companies
32.8
score / 100
Value
13
Quality
52
FCF yld-11%
Earn yld-19%
EV/EBITDA·
ROE-36%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$12.77
Analyst consensus
5 analysts
Strong buy
US$17.00Target US$18.00(+41%)US$21.00
Income statement
RevenueUS$30.4M
Gross profitUS$28.5M94% margin
EBITDA-US$192.2M-632% margin
Net income-US$219.3M-721.3% margin
Valuation
PER (forward)-5.3x
P/Book5.4x
Beta0.45
Balance sheet & cash
Market capUS$1.4B
Total debtUS$311.6M
Free Cash Flow-US$131.7M
Debt / Equity2%
Profitability & ownership
ROE-40.0%
ROA-25.8%
% insiders26.0%
% institutions41.7%
Last declaration on 4 September 2026
Declarations18 total
  • ◆
    Chief Executive OfficerExecutives
    1M USD39SEC
    71,920 shares@ US$15.250.063% mcap100.0% of flowCommon StockSEC:0001140361-26-035816:0
  • ●
    Executives
    0SEC
    30,000 sharesCommon StockSEC:0001449008-26-000004:0
  • ●
    Executives
    0SEC
    30,000 sharesCommon StockSEC:0001602787-26-000004:0
  • ●
    Related company / holdingExecutives
    0SEC
    2,066,250 sharesCommon StockSEC:0002017632-26-000004:0
  • ◆
    Related company / holdingExecutives
    0SEC
    6,561,711 sharesCommon StockSEC:0001231919-26-000783:0
  • ◆
    Related company / holdingExecutives
    0SEC
    970,950 sharesCommon StockSEC:0001231919-26-000783:1
  • ◆
    Related company / holdingExecutives
    0SEC
    553,703 sharesCommon StockSEC:0001231919-26-000783:2
  • ◆
    Related company / holdingExecutives
    0SEC
    908,103 sharesCommon StockSEC:0001231919-26-000783:3
  • ◆
    Related company / holdingExecutives
    0SEC
    367,427 sharesCommon StockSEC:0001231919-26-000783:4
  • ●
    Executives
    0SEC
    2,066,250 sharesCommon StockSEC:0001727440-26-000003:0
  • ●
    Executives
    0SEC
    30,000 sharesCommon StockSEC:0001749623-26-000003:0
  • ●
    Executives
    0SEC
    2,066,250 sharesCommon StockSEC:0001746738-26-000003:0
  • ◆
    Related company / holdingExecutives
    55M USD31SEC
    5,500,000 shares@ US$10.003.18% mcap100.0% of flowCommon StockSEC:0001193125-26-312798:0
  • ◆
    Related company / holdingExecutives
    49M USD37SEC
    4,918,411 shares@ US$10.002.84% mcap93.6% of flowCommon StockSEC:0001231919-26-000783:5
  • ◆
    Related company / holdingExecutives
    3M USD24SEC
    336,965 shares@ US$10.000.19% mcap6.4% of flowCommon StockSEC:0001231919-26-000783:6
  • ◆
    Chief Executive OfficerExecutives
    3M USD30SEC
    286,250 shares@ US$10.00100.0% of flowClass A ordinary sharesSEC:0001140361-24-030027:0
  • ◆
    Chief Business OfficerExecutives
    3M USD19SEC
    286,250 shares@ US$10.00100.0% of flowClass A ordinary sharesSEC:0001140361-24-030023:0
  • ●
    Related company / holdingExecutives
    3M USD10SEC
    286,250 shares@ US$10.00100.0% of flowClass A ordinary sharesSEC:0001140361-24-030029:0

18 of 18 declarations

About Freenome, Inc.

Freenome, Inc. is a biotechnology company that uses artificial intelligence to detect cancer at an early stage. It focuses on developing blood-based screening tests to improve patient outcomes.

Written on 23 July 2026 from the filings and market data available that day. Live figures are in the blocks above.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations

The weekly insider digest, free

One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.